Capmatinib/Touradida belongs to which generation of targeted drugs

Capmatinib (Capmatinib) is an oral small molecule targeted drug, which is a new treatment option in targeted therapy. Its mechanism of action is mainly by specifically inhibiting the tyrosine kinase activity of the MET (hepatocyte growth factor receptor) receptor, thereby effectively inhibiting tumor growth and metastasis caused by MET gene mutations. In the development process of targeted drugs, capmatinib is classified as a new generation of targeted drugs.

Targeted drugs are usually divided into three generations based on their cancer targets and the technical level of development. The first generation of targeted drugs mainly targets basic molecular targets, such as EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase), and their therapeutic effects are usually limited to certain mutation types. Second-generation targeted drugs tend to have stronger selectivity and wider indications, and can also exert better efficacy in some patients with drug-resistant mutations. Capmatinib, as a new generation of MET inhibitor, has demonstrated significant therapeutic effects, especially for patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations (METex14).

Compared with otherMET inhibitors, capmatinib has a stronger targeting effect and can effectively overcome certain resistance mechanisms. In addition, capmatinib is well tolerated during treatment and has ideal side effect control for patients. Capmatinib is considered an advanced drug in targeted therapy against MET mutations due to its effectiveness on specific tumor molecular signatures.

With the development of targeted therapy drugs, targeted drugs have gradually become an important part of tumor treatment. Especially for patients with drug resistance mechanisms, drugs can often provide more effective alternative treatments. The emergence of capmatinib marks an important progress in the field of MET inhibitors and provides new treatment hope for patients with MET mutation-positive tumors.

Keyword tags: Capmatinib, Capmatinib, targeted drugs, MET inhibitors, non-small cell lung cancer, targeted therapy, cancer treatment, generational classification

Reference materials:https://www.drugs.com/mtm/capmatinib.html